RiverVest Venture Partners — 2021 Investments

4 investments dated 2021 · listed companies and verified rows first · show all

Cardialen Inccardialen.comJul 2021

Developing implantable low-energy pain-free atrial cardioverters for atrial fibrillation.

HealthtechSt. Louis, US

M. Brent Shelton(Executive Officer)Paula Skjefte(Executive Officer, Director)Nick Lanners(Executive Officer)Igor Efimov(Director)

BoardEric A. Gulve(Executive Officer, Director)Warren Watson(Director)

Board seatJay Schmelter· per SEC Form D

Co-investorsBroadview Ventures Cultivation Capital

Good Therapeuticsgoodtherapeutics.com 𝕏Series A · Dec 2021 · $11Macquired by Roche

Portfolio company acquired by Roche.

BiotechSeattle, US

John Mulligan(Executive Officer, Director, Promoter)inMitchell Mutz(Director)Nicholas Walrod(Director)

BoardKarl Handelsman(Director)

Board seatJohn McKearn· per SEC Form D

Co-investorsDigitalis Ventures Roche Venture Fund 3x5 Partners Codon Capital

Wugenwugen.comJul 2021 · $115M

Allotera (formerly Wugen) develops allogeneic T-cell therapies.

BiotechHealthtechMedical DevicesSt. Louis, US

Ayman Kabakibi(Executive Officer)inCherry Thomas(Executive Officer)inKumar Srinivasan(Executive Officer, Director)inKeith Vendola(Executive Officer)Daniel M Kemp(Executive Officer, Director)Matthew Cooper(Executive Officer)

Board seatNiall O'DonnellJohn McKearn· per SEC Form D

Co-investorsAisling Capital Alpha Wave Global BioGenerator Ventures Abingworth Fidelity Investments Intermediate Capital Group +1 more

Allotera Therapeuticsalloteratx.comSeries B · Jul 2021 · $170M

St. Louis, US

Co-investorsAisling Capital BioGenerator Ventures LYZZ Capital Abingworth

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.